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A B S T R A C T
Purpose
Colonoscopic surveillance is recommended for individuals with familial colorectal cancer (CRC).
However, the appropriate screening interval has not yet been determined. The aim of this
randomized trial was to compare a 3-year with a 6-year screening interval.
Patients and Methods
Individuals between ages 45 and 65 years with one first-degree relative with CRC age 50 years or two
first-degree relatives with CRC were selected. Patients with zero to two adenomas at baseline were
randomly assigned to one of two groups: group A (colonoscopy at 6 years) or group B (colonoscopy at 3 and
6 years). The primary outcome measure was advanced adenomatous polyps (AAPs). Risk factors studied
included sex, age, type of family history, and baseline endoscopic findings.
Results
A total of 528 patients were randomly assigned (group A, n  262; group B, n  266). Intention-to-treat
analysis showed no significant difference in the proportion of patients with AAPs at the first follow-up
examination at 6 years in group A (6.9%) versus 3 years in group B (3.5%). Also, the proportion of patients
with AAPs at the final follow-up examination at 6 years in group A (6.9%) versus 6 years in group B (3.4%)
was not significantly different. Only AAPs at baseline was a significant predictor for the presence of AAPs
at first follow-up. After correction for the difference in AAPs at baseline, differences between the groups in
the rate of AAPs at first follow-up and at the final examination were statistically significant.
Conclusion
In view of the relatively low rate of AAPs at 6 years and the absence of CRC in group A, we
consider a 6-year surveillance interval appropriate. A surveillance interval of 3 years might be
considered in patients with AAPs and patients with  three adenomas.
J Clin Oncol 33:4188-4193. © 2015 by American Society of Clinical Oncology
INTRODUCTION
Colorectal carcinoma (CRC) is the thirdmost com-
mon cancer and fourth leading cause of overall can-
cer mortality worldwide.1 Various population
screening programs, including fecal occult blood
testing, sigmoidoscopy, and colonoscopy, havebeen
implemented worldwide to detect CRC at an early
stage or to prevent the development of CRC by re-
moval of adenomatous polyps.2-8 Screening by fecal
occult blood testing has been shown to reduce CRC
mortality by approximately 15% and screening by
sigmoidoscopy by approximately 50%.9-12
A substantial proportion (10% to 15%) of pa-
tients with CRC have a positive family history for
CRC without evidence of an inherited CRC
syndrome, such as Lynch syndrome or familial ad-
enomatous polyposis. These individuals have a
moderately increased relative risk (RR) of develop-
ing CRC, varying from 2 to 6, compared with the
general population.Riskdependson theageofonset
of CRC in a first-degree relative (FDR) and on the
number of family members affected with CRC. An
individualwith oneFDRwithCRCdiagnosed at age
 50 years has a reported RR of 3 to 4, whereas an
individual with two FDRs with CRC diagnosed at
any age has an RR of developing CRC of 4 to 6.13-16
Surveillanceof individualswith anelevated risk
for familial CRC is attractive for two reasons, first
because the reported compliance rate with early
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detection programs is higher than that for average-risk individuals,
andsecondbecause theyieldof surveillance ishigher.17-25Althoughall
experts in the field recommend surveillance by colonoscopy, the op-
timal surveillance interval between colonoscopic examinations has
not yet been clearly defined. Current guidelines recommend surveil-
lance at intervals varying from3 to5 to6 years, starting fromthe ageof
45 years.26-28
We therefore initiated a multicenter randomized clinical trial—
the FACTS (Familial Colorectal Cancer Surveillance) study—in the
Netherlands. The objective of this study was to establish the optimal
surveillance interval in familial CRC by comparing occurrence of
advanced adenomatous polyps (AAPs) in patients under surveillance
every 3 years with occurrence in those at an interval of 6 years.
PATIENTS AND METHODS
Study Design
This nationwide randomized controlled trial was coordinated by the
Netherlands Foundation for the Detection of Hereditary Tumors at Leiden
University Medical Center in Leiden. Colonoscopies were performed by
trained gastroenterologists. On the basis of the results of the baseline colono-
scopy, patients were assigned to different study groups (groups A and B).
Patients who had three adenomatous polyps at baseline were excluded and
scheduled for a follow-up colonoscopy at 3 years. Patients with zero, one, or
two adenomatous polyps at baseline were randomly assigned to one of two
groups: Group A underwent colonoscopy at 6 years, whereas group B under-
went follow-up colonoscopies at 3 and 6 years (Fig 1). The study protocol was
approved by themedical ethics committee at LeidenUniversityMedical Cen-
ter and by the local medical ethics committees at collaborating hospitals. The
study complies with the CONSORT checklist published in 2010.
Participants
As described previously,29 all gastroenterologists and general practitio-
ners (GPs) in the Netherlands were informed about the study. Individuals
interested in participating provided both written informed consent and com-
pleted a questionnaire regarding their personal medical and family histories.
The family history was verified with medical and pathology reports. In sus-
pected cases of hereditaryCRC syndrome (patientswithCRCage 50 years),
tumors were analyzed for microsatellite instability (MSI), and patients with
MSI-high tumors were referred to clinical genetic centers.
Colonoscopy
(N = 551)
0-2 adenomas
(n = 528)
Group A
(n = 262)
(n = 221)
(n = 221)
Group B
(n = 266)
(n = 226)
(n = 253)
(n = 225)
Random assignment
Excluded
   CRC
   Hemicolectomy; complication 
      after colonoscopy
   Different screening advice
   Large/multiple/sessile adenoma(s)
   Colitis/IBD
   Suspicion Lynch syndrome
(n = 23)
(n = 1)
(n = 1)
(n = 3)
(n = 11)
(n = 1)
(n = 6)
      Withdrawal
      Lost to follow-up
      Comorbidity
      Different follow-up 
         interval
      Extra colonoscopy 
         in between
(n = 41)*
(n = 7)
(n = 5)
(n = 5)
(n = 11)
(n = 13)
      Withdrawal
      Comorbidity
      Different follow-up 
         interval
(n = 13)*
(n = 7)
(n = 4)
(n = 2)
      Incomplete 
         colonoscopy
(n = 1)*
(n = 1)
      Withdrawal
      Lost to follow-up
      Comorbidity (including 
         1 CRC case)
      FOBT instead of 
         colonoscopy
      Different follow-up 
         interval
      Extra colonoscopy in 
         between
(n = 27)*
(n = 7)
(n = 6)
(n = 5)
(n = 1)
(n = 6)
(n = 2)
Excluded
Excluded
Excluded
Excluded
Fig 1. CONSORT diagram/flowchart.
CRC, colorectal cancer; FOBT, fecal occult
blood test; IBD, inflammatory bowel disease.
(*) Included in intention-to-treat analysis.
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The inclusion period was 2002 to 2007. Individuals were considered
eligible for inclusion if they met the following criteria: age between 45 and 65
years with a positive family history of CRC (ie, one FDR diagnosed with CRC
atage50yearsor twoFDRsdiagnosedwithCRCatanyage). Ineligibilitywas
determined on the basis of additional FDRs or second-degree relatives with
CRC, a personal history of inflammatory bowel disease, previous colorectal
surgery, an FDR with CRC with known MSI, or strong suspicion of Lynch
syndrome (eg, combination of CRC and endometrial cancer).
The collaborating centers selected participants using the abovemen-
tioned criteria. The informed consent of individualsmeeting these criteriawas
sent to the coordinating center. At the coordinating center, the selected pa-
tients from participating centers were alternately allocated, determined by the
inclusion order, to the two groups (A and B) by the study coordinator. Partic-
ipants were not stratified according to sex or participating center. After
completion of the randomization process, participants and their gastroenter-
ologists andGPswere informedabout their allocatedgroupand the timeof the
next scheduled colonoscopy.
Colonoscopic Surveillance and Pathologic Review
The outcomes of all colonoscopic examinations were collected at the
study center. Information was also gathered on the completeness of colono-
scopic examination (visualization of appendiceal opening, cecal valve, and/or
insertion of terminal ileum). If the colon was severely contaminated, the
examination was repeated.
All pathology reports andadenomaswere reviewedbyonepathologist in
Leiden (H.M.). The primary outcome measure was the presence of an ade-
noma with advanced pathology (AAP), defined as an adenoma with either
high-grade dysplasia, tubulovillous or villous architecture, or a size 1 cm in
diameter. The secondary outcomemeasure was the presence of adenomas.
Statistical Analysis
Sample-size calculations were based on the detection of a difference in
percentageofpatientswithAAPsat3yearsof 3.75%(ingroupB)andat6years
of 10% (in group A), with a power of 80% and one-sided level of significance
of .05, requiring 468 and 624 patients, respectively, taking into account a
predicted 25% dropout rate resulting from noncompliance (10%), incidence
ofmultiple polyps (10%), and sessile polyps 3 cmandmalignant adenomas
(5%). During recruitment, we found that the dropout rate was much lower
than expected (approximately 10% instead of 25%), and as a consequence,
fewer patients were required.
According to the principles of intention-to-treat analysis, patients with
follow-up examinations that deviated from the scheduled protocol were ana-
lyzed in their original randomization group. Logistic regression analysis calcu-
lating odds ratios (ORs) was used for comparison of the proportions of
patients developing AAPs (primary outcome) and adenomas (secondary out-
come)at thefirst follow-up(6years ingroupAcomparedwith3years ingroup
B)andfinal follow-upexaminations (6years ingroupAcomparedwith6years
in group B).
Logistic regressionmodelswere also used for the risk factor analysis. The
following risk factors were analyzed as predictors for developing AAPs by the
first follow-up examination (intention-to-treat analysis): sex, age at enroll-
ment, age group ( and 55 years), type of family history, and findings at
baseline (presence of adenoma, adenoma in proximal colon, and AAPs). All
reported P values are two sided, and values  .05 were considered
significant. All analyses were performed using SPSS software (version
22; SPSS, Chicago, IL).
RESULTS
Baseline Findings and Features of Study Groups
Atotal of 551patients accepted the invitation toparticipate in the
FACTS study. Family history was confirmed by medical records in
99% of all patient cases, and family history for CRC could be con-
firmed by pathology reports in 47% of patient cases. All participants
underwent a baseline colonoscopy in the period from 2002 to 2007.
The cecumwas visualized in 93%.
For reasons shown in Figure 1 (upper row), 23 patients were
excluded from the study. Eight of the 23 patients had three adeno-
matous polyps. Follow-up colonoscopy at 3 years was thus advised
according to national guidelines. Of the remaining 528 patients with
zero, one, or two adenomatous polyps at baseline, 262were randomly
assigned to groupA for colonoscopy at 6 years and 266 to group B for
follow-up colonoscopy at both 3 and 6 years (Table 1). Endoscopical
findings at baseline are listed in Table 1. Patients in group B were
found to have more AAPs at baseline than those in group A.
First Follow-Up Examination
A total of 245patients (94%) in groupA returned for a follow-up
colonoscopy. The cecal intubation rate was 95%. Twenty-four (10%)
of the 245patients had either a follow-up interval that deviated by 1
year from the planned scheduled colonoscopy interval or an addi-
tional colonoscopic examination before the scheduled examination.
In groupB, 255 patients (96%) returned for the first follow-up
colonoscopy. The cecal intubation rate was also 95%. Two (0.8%)
of the 255 patients did not comply with the originally defined
follow-up schedule.
Theoutcomesof colonoscopy at 6 years in groupAand3years in
group B were compared in the intention-to-treat analysis. The pro-
portion of patients with adenomas was 26% after 6 years compared
Table 1. Patient Characteristics and Findings at Baseline Colonoscopy
Characteristic
No. of Patients (%)
Group A
(n  262)
Group B
(n  266)†
Age, years
Median 53.0 53.5
IQR 49-57 49-58
Age group, years
 55 174 (66) 157 (59)
 55 88 (34) 109 (41)
Sex
Male 125 (48) 102 (38)
Female 137 (52) 164 (62)
Family history of CRC
One FDR age  50 years 129 (49) 130 (49)
Two FDRs at any age 133 (51) 136 (51)
Two age  70 years 50 (19) 52 (20)
One age  70 and one age  70 years 65 (25) 73 (27)
Two age  70 years 18 (7) 11 (4)
Adenomas
No 216 (82) 220 (83)
Yes 46 (18) 46 (17)
Proximal adenomas
No 246 (94) 249 (94)
Yes 15 (6) 17 (6)
Unknown 1 (0.3)
AAPs
No 257 (98.1) 251 (94.4)
Yes 5 (1.9) 15 (5.6)
Abbreviations: AAP, advanced adenomatous polyp; CRC, colorectal cancer;
FDR, first-degree relative; IQR, interquartile range.
One examination (at 6 years).
†Two examinations (at 3 and 6 years).
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with 13% after 3 years (crude OR, 2.4; 95% CI, 1.5 to 3.9; P .001;
Table 2). The proportion of patients withAAPs after 6 years was 6.9%
comparedwith 3.5% after 3 years (crudeOR, 2.0; 95%CI, 0.89 to 4.7;
P .09). There was one patient case of incident in CRC group B after
3 years, a poorly differentiated tumor in the splenic flexure (stage
pT3N0). For the purposes of analysis, this patient case was included
with the AAPs.
AAPs at baseline were found in five (1.9%) of 262 patients in
groupAand in 15 (5.6%)of 266 patients in groupB.We corrected for
thisfinding in abivariable logistic regressionanalysiswith studygroup
andAAPs(asdichotomousvariable) in themodel.After correction for
the differences in presence of AAPs at baseline between the two
groups, the difference in the presence of AAPs at first follow-up was
statistically significant (adjusted OR, 2.44; 95% CI, 1.03 to 5.78;
P .044).
Second Follow-Up Examination
A total of 235 (88%) of the original 266 patients in the group
requiring two examinations (group B) returned for their second
follow-up colonoscopy. The cecal intubation rate was 96%.
Ten (4%) of 235 patients had different follow-up intervals or
incomplete or additional unplanned colonoscopies. At the second
examination of group B at 6 years, a lower proportion of patients had
adenomas and AAPs compared with the single-examination group
(group A) at 6 years. However, the differences were not significant in
the intention-to-treat analysis (Table 2). After correction for the dif-
ference in presence of AAPs at baseline between the two groups, the
difference in the presence of AAPs at the final examination was statis-
tically significant (adjusted OR, 2.61; 95% CI, 1.06 to 6.45; P .038;
Table 2).
Risk Factors
Sex, age, type of family history, and findings at baseline colonos-
copy were analyzed as individual risk factors for the development of
AAPs at the first follow-up examination in group A at 6 years and in
group B at 3 years. Patients with a different follow-up interval or with
additional unplanned colonoscopies were included in the intention-
to-treat analysis. Only AAPs were identified as a predictor for the
development of AAPs by first follow-up (OR, 5.21; 95% CI, 1.61 to
16.87; P .006; Table 3).
DISCUSSION
Hereditary factors play a role in a substantial proportion of patient
cases of CRC. Although 3% to 5% of all patient cases of CRC result
from hereditary cancer syndromes, such as Lynch syndrome and
polyposis syndromes, 5%to10%ofall patient casesofCRCare caused
by a combination of hereditary and environmental factors; these are
collectively referred to as familial CRC.The lifetime risk of developing
CRC for individuals with hereditary CRC syndromes varies from
approximately 50% in Lynch syndrome to 90% in familial adenoma-
touspolyposis. In familialCRC, the lifetime risk is approximately 10%
to 20%, depending on the age of onset of CRC in the FDR and on the
number of affected FDRs.13,15,16
The frequency of a significant family history of CRC (ie, one
FDR with early-onset CRC or two FDRs with CRC) in the general
population age between 45 and 70 years is approximately 2%.30
The expected number of individuals with familial CRC in the
United States is 2.7 million.
British investigators have shown that colonoscopic surveil-
lance in high-risk families leads to a reduction in the incidence of
CRC and CRC-related mortality by 80%.31 However, the study,
which is the only available investigation in this field, did not in-
clude a control group, and the 80% reduction was calculated by
comparing the observed incidence of CRC and mortality in the
Table 2. Findings of Follow-Up Colonoscopy
Finding
First Follow-Up Examination Second Follow-Up
Examination
Group B
(n  234)
Group A
(n  245)
Group B
(n  255)†
Adenomas, No. (%) 63 (26) 32 (13) 46 (20)
Crude OR (95% CI)
6-year A v 3-year B 2.4 (1.5 to 3.9)
6-year A v 6-year B 1.4 (0.92 to 2.2)
AAPs, No. (%) 17 (6.9) 9 (3.5) 8 (3.4)
Crude OR (95% CI)
6-year A v 3-year B 2.0 (0.89 to 4.7)
6-year A v 6-year B 2.1 (0.89 to 5.0)
Adjusted OR (95% CI)
6-year A v 3-year B 2.44 (1.03 to 5.78)
6-year A v 6-year B 2.61 (1.06 to 6.45)
Abbreviations: AAP, advanced adenomatous polyp; OR, odds ratio.
At 6 years.
†At 3 years.
Table 3. Risk Factor Analyses for Presence of AAPs at First
Follow-Up Colonoscopy
Risk Factor at Enrollment
No. With AAPs of
No. Examined (%)
Univariable
OR (95% CI) P
Sex
Male 15 of 217 (6.9) 1.8 (0.83 to 4.1) .14
Female 11 of 283 (3.9) 1.0
Age, years
 55 18 of 313 (5.8) 1.0
 55 8 of 187 (4.3) 0.7 (0.31 to 1.7) .48
Age 1.006 (0.94 to 1.1) .88
Family history of CRC
One FDR age  50 years 9 of 241 (3.7) 1.0
Two FDRs any age 17 of 259 (6.6) 1.8 (0.79 to 4.1) .160
Two age  70 years 7 of 95 (7.4) 2.1 (0.74 to 5.7) .17
One age  70 and one
age  70 years 7 of 135 (5.2) 1.4 (0.51 to 3.9) .51
Two age  70 years 3 of 29 (10.3) 3.0 (0.76 to 12) .12
Adenomas
No 19 of 413 (4.6) 1.0
Yes 7 of 87 (8.0) 1.8 (0.74 to 4.5) .19
Proximal adenomas
No 24 of 468 (5.1) 1.0
Yes 2 of 31 (6.5) 1.3 (0.29 to 5.7) .75
Unknown 1
AAPs
No 22 of 480 (4.6) 1.0
Yes 4 of 20 (20) 5.2 (1.6 to 16.87) .006
Abbreviations: AAP, advanced adenomatous polyp; CRC, colorectal cancer;
OR, odds ratio.
One FDR age  50 years  reference group.
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high-risk cohort under surveillance with those expected in the
absence of surveillance.
Although colonoscopic surveillance in familial CRC is currently
recommended by all experts, the appropriate surveillance interval has
not yet been clearly established. To our knowledge, our multicenter
nationwide randomized trial is the first study to compare different
surveillance intervals in familial CRC.Theparticipantswere primarily
selected by GPs and gastroenterologists from all parts of the Nether-
lands. The study population is therefore representative for all such
individuals in theNetherlands.The intention-to-treat analysis showed
that there was no statistically significant difference in the presence of
AAPs at the first follow-up examination between individuals whohad
colonoscopy at 6 years compared with those who underwent colono-
scopy at 3 years.However, ifwe corrected for the difference ofAAPs at
baseline, the difference became statistically significant.
There was also no statistically significant difference in the pres-
ence of AAPs at the final examination at 6 years between the individ-
uals who had one follow-up examination 6 years after the baseline
colonoscopy and those who had two follow-up examinations after 3
and 6 years. After correction for the difference in presence of AAPs at
baseline, the difference became statistically significant.
Several cautionary notes must be made with regard to our find-
ings. First, the fact that more participants in the 6-year group com-
pared with the 3-year group underwent a colonoscopy that deviated
from the original protocol may have influenced the outcome.
A clinically important finding was the observation of a relatively
low absolute rate (6.9%) of AAPs in group A, in addition to the
absence of CRC in this group. Although there was a significant differ-
ence inAAPsbetween the twogroups, inviewof this relatively lowrate
of AAPs and the absence of CRC in group A, we consider a 6-year
surveillance interval appropriate for individuals with familial CRC.
However, a 3-year surveillance interval might be recommended for
patientswithAAPs. Future studies in larger groups should compare6-
and 10-year surveillance intervals.
A strength of this study is its randomized design. Moreover,
family history was verified by medical reports in 99% of all patient
cases and by pathology reports in almost 50% of patient cases. All
adenomas identified at baseline and follow-up colonoscopies were
revised by one pathologist.
A possible weakness of the study is that the colonoscopies were
performed in various university and regional hospitals in the Nether-
lands. However, all colonoscopic examinations were performed by
well-trained gastroenterologists, and appropriate cecal intubation
rates were achieved. Moreover, additional imaging was performed if
the colonoscopy was incomplete.
A second weakness of the study is that there were a few patient
cases of early-onset CRC in which MSI or immunohistochemical
analysis of the mismatch-repair proteins was not performed. These
patient cases of CRC may have represented Lynch syndrome. How-
ever, because the detection rate of a pathogenicmismatch-repairmu-
tation inpatientswithCRCbefore the ageof 50years is only 6%,32 and
the possible patient cases of Lynch syndrome were randomly distrib-
uted among the two arms of the study, we do not expect our findings
to be significantly affected by inclusion of patients with incidental
Lynch syndrome.
Athirdlimitationofthestudyisthatthestatisticalpowerwaslimited,
andAAPs are a surrogate outcome toCRCandCRC-relatedmortality.
In summary, and taking all the findings of this study into consid-
eration, a 6-year colonoscopic surveillance interval can be recom-
mended in familial CRC. Future studies should address the upper age
limit for surveillance and, in particular, determine the cutoff point at
which the advantages of surveillance are outweighed by disadvantages
of colonoscopic surveillance.
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